Cargando…

Patient-reported outcome measures for use in clinical trials of SLE: a review

Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE...

Descripción completa

Detalles Bibliográficos
Autores principales: Izadi, Zara, Gandrup, Julie, Katz, Patricia P, Yazdany, Jinoos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109821/
https://www.ncbi.nlm.nih.gov/pubmed/30167315
http://dx.doi.org/10.1136/lupus-2018-000279
_version_ 1783350386277482496
author Izadi, Zara
Gandrup, Julie
Katz, Patricia P
Yazdany, Jinoos
author_facet Izadi, Zara
Gandrup, Julie
Katz, Patricia P
Yazdany, Jinoos
author_sort Izadi, Zara
collection PubMed
description Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE and to evaluate their responsiveness to interventions in randomised controlled trials (RCTs). A systematic review was undertaken using full original papers in English identified from three databases: MEDLINE, EMBASE and PubMed. Studies describing the validation of HRQoL measures in English-speaking adult patients with SLE and SLE drug RCTs that used an HRQoL measure were retrieved. Twenty-five validation papers and 26 RCTs were included in the indepth review evaluating the measurement properties of 4 generic (Medical Outcomes Study Short-Form 36 (SF36), Patient Reported Outcomes Measurement Information System (PROMIS) item-bank, EuroQol-5D, and Functional Assessment of Chronic Illness Therapy-Fatigue) and 3 disease-specific (Lupus Quality of Life (LupusQoL), Lupus Patient Reported Outcomes, Lupus Impact Tracker (LIT)) instruments. All measures had good convergent and discriminant validity. PROMIS provided the strongest evidence for known-group validity and reliability among generic instruments; however, data on its responsiveness have not been published. Across measures, standardised response means were generally indicative of poor-moderate sensitivity to longitudinal change. In RCTs, clinically important improvements were reported in SF36 scores from baseline; however, between-arm differences were frequently non-significant and non-important. SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties, but few measures aside from the SF36 have been incorporated into clinical trials. This review highlights the importance of incorporating a broader range of SLE-specific HRQoL measures in RCTs and warrants further research that focuses on longitudinal responsiveness of newer instruments.
format Online
Article
Text
id pubmed-6109821
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61098212018-08-30 Patient-reported outcome measures for use in clinical trials of SLE: a review Izadi, Zara Gandrup, Julie Katz, Patricia P Yazdany, Jinoos Lupus Sci Med Review Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE and to evaluate their responsiveness to interventions in randomised controlled trials (RCTs). A systematic review was undertaken using full original papers in English identified from three databases: MEDLINE, EMBASE and PubMed. Studies describing the validation of HRQoL measures in English-speaking adult patients with SLE and SLE drug RCTs that used an HRQoL measure were retrieved. Twenty-five validation papers and 26 RCTs were included in the indepth review evaluating the measurement properties of 4 generic (Medical Outcomes Study Short-Form 36 (SF36), Patient Reported Outcomes Measurement Information System (PROMIS) item-bank, EuroQol-5D, and Functional Assessment of Chronic Illness Therapy-Fatigue) and 3 disease-specific (Lupus Quality of Life (LupusQoL), Lupus Patient Reported Outcomes, Lupus Impact Tracker (LIT)) instruments. All measures had good convergent and discriminant validity. PROMIS provided the strongest evidence for known-group validity and reliability among generic instruments; however, data on its responsiveness have not been published. Across measures, standardised response means were generally indicative of poor-moderate sensitivity to longitudinal change. In RCTs, clinically important improvements were reported in SF36 scores from baseline; however, between-arm differences were frequently non-significant and non-important. SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties, but few measures aside from the SF36 have been incorporated into clinical trials. This review highlights the importance of incorporating a broader range of SLE-specific HRQoL measures in RCTs and warrants further research that focuses on longitudinal responsiveness of newer instruments. BMJ Publishing Group 2018-08-21 /pmc/articles/PMC6109821/ /pubmed/30167315 http://dx.doi.org/10.1136/lupus-2018-000279 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Review
Izadi, Zara
Gandrup, Julie
Katz, Patricia P
Yazdany, Jinoos
Patient-reported outcome measures for use in clinical trials of SLE: a review
title Patient-reported outcome measures for use in clinical trials of SLE: a review
title_full Patient-reported outcome measures for use in clinical trials of SLE: a review
title_fullStr Patient-reported outcome measures for use in clinical trials of SLE: a review
title_full_unstemmed Patient-reported outcome measures for use in clinical trials of SLE: a review
title_short Patient-reported outcome measures for use in clinical trials of SLE: a review
title_sort patient-reported outcome measures for use in clinical trials of sle: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109821/
https://www.ncbi.nlm.nih.gov/pubmed/30167315
http://dx.doi.org/10.1136/lupus-2018-000279
work_keys_str_mv AT izadizara patientreportedoutcomemeasuresforuseinclinicaltrialsofsleareview
AT gandrupjulie patientreportedoutcomemeasuresforuseinclinicaltrialsofsleareview
AT katzpatriciap patientreportedoutcomemeasuresforuseinclinicaltrialsofsleareview
AT yazdanyjinoos patientreportedoutcomemeasuresforuseinclinicaltrialsofsleareview